Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine paravertebral nerve block for postherpetic neuralgia
ChiCTR2100044554Phase 4Recruiting
- Sponsor
- Zhangjiagang First People's Hospital
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of esketamine in postherpetic neuralgia (PHN) (2 arms), sponsored by Zhangjiagang First People's Hospital. Primary endpoints: Pain effect and Number of nerve block treatments. Started Mar 2021; status: recruiting.
02
Drugs
esketamine
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on ChiCTR2100044554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044554.